Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis

• Published in: BMC pediatrics Vol. 20; no. 1; p. 176
• Main Authors: Feng, Xinying, Wu, Yunjiao, Zhang, Jingru, Li, Jiapeng, Zhu, Guanghua, Fan, Duanfang, Yang, Changqing, Zhao, Libo
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.04.2020; BioMed Central; BMC
• Subjects: Adolescent; Area under the concentration-time curve; Busulfan; Busulfan - adverse effects; Child; Child health; Child, Preschool; Chromatography; Clinical outcomes; Comparative analysis; Drug dosages; Efficacy; Hematopoietic stem cell transplantation; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Incidence; Infant; Medical research; Meta-analysis; Patients; Pediatrics; Prospective Studies; Review; Stem cell transplantation; Stem cells; Transplantation Conditioning - adverse effects; Transplants & implants; Veno-occlusive disease; Colombia; United States > US; Veno-occlusive disease; Efficacy; Area under the concentration-time curve; Busulfan; Meta-analysis
• ISSN: 1471-2431; 1471-2431
• DOI: 10.1186/s12887-020-02028-6

Busulfan (Bu) is a key component of several conditioning regimens used before hematopoietic stem cell transplantation (HSCT). However, the optimum systemic exposure (expressed as the area under the concentration-time curve [AUC]) of Bu for clinical outcome in children is controversial. Research on pertinent literature was carried out at PubMed, EMBASE, Web of science, the Cochrane Library and ClinicalTrials.gov. Observational studies were included, which compared clinical outcomes above and below the area under the concentration-time curve (AUC) cut-off value, which we set as 800, 900, 1000, 1125, 1350, and 1500 μM × min. The primary efficacy outcome was notable in the rate of graft failure. In the safety outcomes, incidents of veno-occlusive disease (VOD) were recorded, as well as other adverse events. Thirteen studies involving 548 pediatric patients (aged 0.3-18 years) were included. Pooled results showed that, compared with the mean Bu AUC (i.e., the average value of AUC measured multiple times for each patient) of > 900 μM × min, the mean AUC value of < 900 μM × min significantly increased the incidence of graft failure (RR = 3.666, 95% CI: 1.419, 9.467). The incidence of VOD was significantly decreased with the mean AUC < 1350 μM × min (RR = 0.370, 95% CI: 0.205-0.666) and < 1500 μM × min (RR = 0.409, 95% CI: 0182-0.920). In children, Bu mean AUC above the cut-off value of 900 μM × min (after every 6-h dosing) was associated with decreased rates of graft failure, while the cut-off value of 1350 μM × min were associated with increased risk of VOD, particularly for the patients without VOD prophylaxis therapy. Further well-designed prospective and multi centric randomized controlled trials with larger sample size are necessary before putting our result into clinical practices.